Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BioPharmaDive
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioPharmaDive
-
With $420M in Q4 revenues,
$VRTX's cystic fibrosis drug Trikafta performed 5x better than expected — and capped off an 8-year growth story for the biotech's CEO.https://www.biopharmadive.com/news/vertex-trikafta-launch-cystic-fibrosis-leiden/571452/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO.https://www.biopharmadive.com/news/biotech-diversity-leadership-women-bio-report/571495/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Competition is heating up for copycats to
$RHHBY's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting$AMGN$PFE$BIIBhttps://www.biopharmadive.com/news/amgen-pfizer-biosimilar-growth-herceptin-avastin/571502/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioPharma Dive proslijedio/la je Tweet
If you haven't yet, check out
@BioPharmaDive's latest deep dive. After years being all-in on brain drugs, big pharma pulled back. Is a return on the horizon? And, if so, what effects might it have on drug research?#biotech#pharma#neurosciencehttps://www.biopharmadive.com/news/pharma-neuroscience-retreat-return-brain-drugs/570250/ …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Spinraza rivals and Tecfidera patent challenges were in the spotlight as
$BIIB provided few details about its planned filing for aducanumab.https://www.biopharmadive.com/news/biogen-earnings-aducanumab-tecfidera-spinraza/571413/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
$LLY's top scientist, however, set low expectations the drug will show a clear benefit.https://www.biopharmadive.com/news/lilly-preventive-alzheimers-dian-tu-study-within-weeks/571411/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biotech execs see a new era of neuroscience advances ahead. But it's hard to pinpoint what would cause pharma to dive back in — and what ripples that would create.https://www.biopharmadive.com/news/pharma-neuroscience-retreat-return-brain-drugs/570250/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.https://www.biopharmadive.com/news/decibel-ceo-steps-down-job-cuts-restructuring/571332/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Another 100 infants received
$NVS' Zolgensma in the fourth quarter, supported by broad insurance coverage and more newborn screening.https://www.biopharmadive.com/news/novartis-zolgensma-gene-therapy-sales-momentum/571302/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioPharma Dive proslijedio/la je Tweet
Big pharma backed away from brain drugs. Is a return in sight? https://www.biopharmadive.com/news/pharma-neuroscience-retreat-return-brain-drugs/570250/ … via
@BioPharmaDive and@realjacobbellHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The pharma is targeting deals between $1 billion and $5 billion every quarter, its CFO told Reuters, although the focus will be on clinical-stage assetshttps://bit.ly/369fzM4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
An upcoming FDA advisory meeting will be a key test for Intercept's ambitions to become the first drugmaker with an approved therapy for the liver diseasehttps://bit.ly/2FYNfB9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioPharma Dive proslijedio/la je Tweet
"Are you all on Vascepa?" asked
$AMRN CEO John Thero to a room full of investors Wednesday ... Check out@realJacobBell and@AndrewE_Dunn's last dispatch from#JPM20 for more:https://www.biopharmadive.com/news/jpm-2020-amarin-vascepa-orchard-biohaven-migraine-day-3/570559/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At
#JPM20$FOLD predicted its crown jewel - a Pompe disease drug - has opportunity for $1B to $2B in peak saleshttps://www.biopharmadive.com/news/jpm20-neurosciences-decade-a-biotechs-crown-jewel-and-ionis-gets-sel/570445/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
After a decade of research,
$NKTR said it will withdraw its application for oxycodegol and make no further investment in the drug.https://www.biopharmadive.com/news/nektar-withdraw-oxycodegol-fda-advisory-committee-vote/570497/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Andelyn Biosciences, named after two children treated with gene therapy at
@nationwidekids, will operate as a for-profit subsidiary of the Ohio-based hospital.https://www.biopharmadive.com/news/nationwide-childrens-gene-therapy-manufacturing-andelyn-launch/570397/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Though
$GLPG is tied to a 10-year, $5B research pact with$GILD, its CEO says there's still some "wheeling and dealing" left to do.https://www.biopharmadive.com/news/galapagos-dealmaking-jpm-onno-stolpe-gilead/570484/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioPharma Dive proslijedio/la je Tweet
The 2020s will be neuroscience's decade, Roche's Bill Anderson bullishly predicted Tuesday at
#JPM20, which featured other updates from$FOLD and$IONShttps://www.biopharmadive.com/news/jpm20-neurosciences-decade-a-biotechs-crown-jewel-and-ionis-gets-sel/570445/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
A quiet start to
#JPM20, often viewed as a gauge of dealmaking interest, could spark some doubts, however.https://www.biopharmadive.com/news/pharma-deals-record-continue-2020-ey/570019/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.